Gyre Therapeutics awards 40,000 stock options
Gyre Therapeutics director Claire Weston received a grant of stock options to purchase 40,000 shares of common stock at an exercise price of $6.11 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gyre Therapeutics director Claire Weston received a grant of stock options to purchase 40,000 shares of common stock at an exercise price of $6.11 per share. The options vest in 36 equal monthly installments through August 3, 2029 and expire on August 3, 2036, leaving her with options on 40,000 shares.
Insider Trade Summary
Grant/Award: 40,000 shares
Grant/Award
1 txn
Insider
Weston Claire
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 40,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 contracts (Direct)
Footnotes (1)
- F1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 3, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Key Figures
Option shares granted: 40,000 shares
Exercise price: $6.11 per share
Vesting period: 36 months
+2 more
5 metrics
Option shares granted
40,000 shares
Stock option grant to director Claire Weston for common stock
Exercise price
$6.11 per share
Exercise price of the stock options granted to Claire Weston
Vesting period
36 months
Options vest in 36 equal monthly installments through August 3, 2029
Expiration date
August 3, 2036
Final expiration date of the stock options if not exercised
Options following transaction
40,000 options
Total stock options held from this grant after the reported transaction
Key Terms
Stock Option (Right to Buy), vest in 36 equal monthly installments, exercise price, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) reported for the grant"
vest in 36 equal monthly installments financial
"will vest in 36 equal monthly installments through August 3, 2029"
exercise price financial
"conversion or exercise price of 6.1100 per share applies to the options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration date of the option is reported as 2036-08-03"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did GYRE disclose for director Claire Weston?
Claire Weston received a grant of stock options covering 40,000 shares of Gyre Therapeutics common stock. These options are a compensation award, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price.
What is the exercise price and term of Claire Weston’s GYRE stock options?
The stock options have an exercise price of $6.11 per share and an expiration date of August 3, 2036. Weston may exercise vested portions any time before expiration, subject to the company’s usual equity plan and service conditions.
How do Claire Weston’s GYRE stock options vest over time?
The options vest in 36 equal monthly installments through August 3, 2029. Each month a portion becomes exercisable, provided Claire Weston continues serving Gyre Therapeutics through each vesting date, aligning the award with ongoing board service.
How many GYRE stock options does Claire Weston hold after this grant?
After this grant, Claire Weston holds 40,000 stock options as reported for this award. This figure reflects the total option units from the grant, which will vest over three years and remain exercisable until their 2036 expiration date.
Were Claire Weston’s GYRE options granted under a Rule 10b5-1 trading plan?
The disclosure indicates the Rule 10b5-1 checkbox is not marked, and the footnote describes only vesting terms. It therefore characterizes the transaction simply as a compensation grant, without reference to any pre-arranged trading plan for sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
